Current Oncology Reports

Cytokines in the Treatment of Melanoma

Salah-Eddine Bentebibel, Adi Diab

Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need

F. Serra, S. Barruscotti, T. Dominioni, A. Zuccarini, P. Pedrazzoli, S. Chiellino

Acupuncture for Cancer-Related Anorexia: a Review of the Current Evidence

Wenli Liu, Gabriel Lopez, Santhosshi Narayanan, Aiham Qdaisat, Yimin Geng, Shouhao Zhou, Michael Spano, Susan Underwood, Marie G. Eclache, Rony Dev, Shalini Dalal, Eduardo Bruera, Lorenzo Cohen

Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention

Tatiana R. Perry, Michelle L. Roberts, Bipin Sunkara, Ragasnehith Maddula, Tyson McLeish, Jose Gomez, Julliette Lucas, David Rayan, Sahishnu Patel, Mingyu Liang, Zeljko J. Bosnjak, Sherry-Ann Brown

Cardiovascular Toxicities of CAR T-cell Therapy

Nikita P. Patel, Peter G. Doukas, Leo I. Gordon, Nausheen Akhter

Cardiotoxicity of Immune Checkpoint Inhibitors

Rushin P. Patel, Rohan Parikh, Krishna S. Gunturu, Rana Zouveenoor Tariq, Sourbha S. Dani, Sarju Ganatra, Anju Nohria

Global Perceptions of Women on Breast Cancer and Barriers to Screening

Mariah Mascara, Constantina Constantinou

Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence?

J. Palussière, M. Cazayus, S. Cousin, M. Cabart, F. Chomy, V. Catena, X. Buy

Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?

Victor Rodriguez-Freixinos, Alia Thawer, Jaume Capdevila, Diego Ferone, Simron Singh

How to Manage Small Intestine (Jejunal and Ileal) Neuroendocrine Neoplasms Presenting with Liver Metastases?

Bruno Niederle, Andreas Selberherr, Martin B. Niederle

Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers

Casey M Cosgrove, David Barrington, Floor J. Backes

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs

Jemma Longley, Peter W. M. Johnson

Rare Adverse Events with Programmed Death-1 and Programmed Death-1 Ligand Inhibitors: Justification and Rationale for a Systematic Review